Kennedy Dissolves 75 Health Advisory Panels as Courts Block Transgender Care Funding Cuts

What Happens Next

• →With 75 advisory panels dissolved, FDA and CDC lose standing expert review capacity for drug approvals, outbreak response protocols, and dietary guidelines, forcing agency staff to rely on ad hoc internal reviews that slow regulatory timelines by weeks to months.
• →The threatened disbandment of the CDC vaccine advisory committee (ACIP) removes the body that sets the U.S. childhood immunization schedule; without it, state health departments and insurers lose their primary reference for coverage decisions, fragmenting vaccine policy across jurisdictions.
• →Hospitals in the 21 states shielded by the federal court ruling continue gender-transition care services, creating a widening geographic disparity in access that accelerates patient migration to those states and intensifies state-level legislative battles over transgender healthcare bans.
• →The FDA's retreat on indoor tanning regulation signals broader deregulatory intent under Kennedy's HHS, emboldening industry lobbying efforts across cosmetics, supplements, and food additives to push for rollbacks of pending or proposed safety rules.

Near-term: Within 1-3 months, federal agencies lack quorum or standing membership on dissolved panels, stalling pending reviews of drug applications, dietary guidelines updates, and environmental health assessments. States begin filing additional lawsuits challenging specific policy changes made without advisory input. Long-term: Over 2-5 years, the institutional knowledge embedded in disbanded advisory panels is permanently lost as experts disperse to private sector and academia. A parallel ecosystem of private advisory bodies and state-level panels emerges, creating a structurally fragmented U.S. health regulatory landscape where federal guidance carries diminished authority relative to state and industry standards.